Abstract
Pooled data from trials comparing nesiritide with dobutamine for treatment of acute decompensated congestive heart failure were combined with national hospital cost data in an economic model. Results indicate that the acquisition cost of nesiritide is fully offset by decreased hospital costs.
Publication types
-
Comparative Study
-
Meta-Analysis
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acute Disease
-
Age Distribution
-
Aged
-
Cardiotonic Agents / economics*
-
Cardiotonic Agents / therapeutic use*
-
Dobutamine / economics*
-
Dobutamine / therapeutic use*
-
Drug Costs / statistics & numerical data
-
Female
-
Heart Failure / drug therapy*
-
Heart Failure / economics*
-
Heart Failure / mortality
-
Hospital Costs / statistics & numerical data*
-
Humans
-
Life Expectancy
-
Male
-
Middle Aged
-
Models, Econometric
-
Monte Carlo Method
-
Natriuretic Agents / economics*
-
Natriuretic Agents / therapeutic use*
-
Natriuretic Peptide, Brain
-
Patient Admission / economics
-
Predictive Value of Tests
-
Sex Distribution
-
Survival Analysis
-
Treatment Outcome
-
United States / epidemiology
-
Value of Life
Substances
-
Cardiotonic Agents
-
Natriuretic Agents
-
Natriuretic Peptide, Brain
-
Dobutamine